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Abstract
Background: Deterioration of peroxisomal β-oxidation activity causes an accumulation of very
long chain saturated fatty acids (VLCSFA) in various organs. We have recently reported that the
levels of VLCSFA in the plasma and/or membranes of blood cells were significantly higher in
patients with metabolic syndrome and in patients with coronary artery disease than the controls.
The aim of the present study is to investigate the effect of VLCSFA accumulation on inflammatory
and oxidative responses in VLCSFA-accumulated macrophages derived from X-linked
adrenoleukodystrophy (X-ALD) protein (ALDP)-deficient mice.
Results: Elevated levels of VLCSFA were confirmed in macrophages from ALDP-deficient mice.
The levels of nitric oxide (NO) production stimulated by lipopolysaccharide (LPS) and interferon-
γ (IFN-γ), intracellular reactive oxygen species (ROS), and pro-inflammatory cytokines, including
tumor necrosis factor-α (TNF-α), interluekin-6 (IL-6), and interleukin-12p70 (IL-12p70), were
significantly higher in macrophages from ALDP-deficient mice than in those from wild-type mice.
The inducible NO synthase (iNOS) mRNA expression also showed an increase in macrophages
from ALDP-deficient mice.
Conclusion: These results suggested that VLCSFA accumulation in macrophages may contribute
to the pathogenesis of inflammatory diseases through the enhancement of inflammatory and
oxidative responses.
Background
Deterioration in peroxisomal β-oxidation activity plays a
critical role in ageing- and inflammatory-related disorders
through the accumulation of very long chain saturated
fatty acids (VLCSFA) in various organs [1,2]. VLCSFA with
more than 22 carbon atoms are almost exclusively oxi-
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dized in peroxisomes [3]. Accumulation of VLCSFA is
reported to be associated with increased membrane
microviscosity and membrane disorders [4,5]. Indeed,
hexacosanoic acid (C26:0), a VLCSFA, is accumulated in
plasma, the membranes of blood cells, and/or tissue of
patients with X-ALD, which is characterized by progressive
demyelination and adrenal insufficiency [6,7].
In patients with X-ALD, the expression of pro-inflamma-
tory cytokines, including tumor necrosis factor-α (TNF-α)
and interleukin-1β (IL-1β), in activated macrophages and
astrocytes was up-regulated in brain lesions [8]. As well as
increased expression of inducible nitric oxide synthesis
(iNOS), pro-inflammatory cytokines, such as TNF-α, IL1-
β, and IL-6, were observed in astrocytes and microglia
[9,10]. Furthermore, TNF-α production in peripheral
blood mononuclear cells (PBMC) after lipopolysaccha-
ride (LPS) administration was significantly higher in X-
ALD patients than in controls [11,12]. The production of
NO and superoxide anion (O2
-) after treatment with LPS
and oxidized low-density lipoprotein (OxLDL) was
increased in C26:0-enriched rat glial cells [13]. These
results suggested that VLCSFA accumulation in various
cells including macrophages, microglia, and astrocytes
from X-linked ALD is associated with enhanced inflam-
matory responses.
Monocytes/macrophages also play a key role in the proc-
ess of atherosclerotic diseases [14,15]. Activated macro-
phages in atherosclerotic lesions produce a wide variety of
mediators, including NO [16], reactive oxygen species
(ROS) [17], and pro-inflammatory cytokines [18]. We
recently reported that C26:0 is accumulated in the plasma
and membranes of blood cells in patients with metabolic
syndrome and in patients with coronary artery disease
[19,20]. These results suggest that VLCSFA accumulation
may play an important role in lifestyle related diseases,
such as metabolic syndrome and atherosclerotic diseases;
however, the precise mechanism by which VLCSFA accu-
mulation contributes to the initiation and progression of
such diseases is uncertain. Therefore, the present study
was conducted to investigate the effect of endogenous
VLCSFA accumulation on inflammatory and oxidative
responses in macrophages derived from ALDP-deficient
mice [21].
Methods
Reagents
RPMI1640 media, fetal bovine serum (FBS), penicillin,
streptomycin, phosphate buffered saline without calcium
and magnesium (PBS (-)), and Hank's balanced salt solu-
tion (HBSS) were purchased from Gibco (Carlsbad, CA,
USA). Thioglycollate was obtained from Becton Dickin-
son (Cockeysville, MD, USA). Phorbol myristate acetate
(PMA), dimethyl sulfoxide (DMSO), 2',7'-dichlorofluo-
rescin diacetate (DCFH-DA), Escherichia coli lipopolysac-
charide (LPS, 0111:B4), sulfanilamide,
naphthylethylenediamine dihydrochloride, phosphoric
acid (H3PO4), sodium nitrite (NaNO2), boron trifluoride
methanol, nonacosanoic acid, and tricosenoic acid were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Murine recombinant interferon (IFN)-γ was purchased
from BD Pharmingen (San Diego, CA, USA).
Mice
ALDP-deficient mice [21] backcrossed to C57BL/6J for 10
generations were obtained from the National Institute for
Longevity Sciences of the National Center for Geriatrics
and Gerontology (Obu City, Aichi, Japan) and males aged
12 to 14 weeks were used for experiments. Male C57BL/
6J, wild-type counterparts, were purchased from Charles
River Laboratory Inc. (Japan). All animals were housed
and maintained in specific pathogen-free condition at a
controlled temperature (23 ± 2°C), on a 12 h light/dark
cycle, and fed a normal chow diet (Funabashi Farm,
Chiba, Japan) and tap water ad libitum. The animal exper-
iments were approved by the Morinaga Milk Industry Ani-
mal Research Committee, and the mice were maintained
according to the guides for the care and use of laboratory
animals of Morinaga Milk Industry Co., Ltd.
Cell Culture
To isolate thioglycollate-elicited murine peritoneal exu-
date macrophages (MPMs), mice were injected intraperi-
toneally with 2 ml of 4% (wt/vol) thioglycollate solution.
Four days later, they were sacrificed by anesthetizing with
ether and their abdominal cavities washed out twice with
5 ml of cold PBS (-). The peritoneal lavage fluid was cen-
trifuged at 1200 rpm, 4°C for 10 min. After washing twice,
cell pellets were gently resuspended at 1 × 106 cells/ml in
RPMI1640 medium with 2 mM L-glutamine, supple-
mented with 10% endotoxin-free FBS, 100 U/ml penicil-
lin and 100 μg/ml streptomycin. To recover adherent
cells, MPMs were incubated for 2 h and washed with PBS(-
) twice, and non-adherent cells were removed by aspira-
tion. All culture incubations were performed in a humid-
ified 37°C, 5% CO2 incubator unless otherwise stated.
Cell viability was checked using Tripan blue exclusion and
the viability was greater than 95%.
Measurements of Plasma Lipid and Glucose Levels
Mice were fasted for 16 h and blood samples were har-
vested by cardiac puncture after ether anesthesia and col-
lected into EDTA-disodium containing tubes. Samples
were centrifuged at 3000 rpm for 15 min to obtain
plasma. Plasma lipid such as triglyceride (TG), total cho-
lesterol (TC), very low-density lipoprotein cholesterol
(VLDL-C), low-density lipoprotein cholesterol (LDL-C),
and high-density lipoprotein cholesterol (HDL-C) were
measured by the HPLC column method at Skylite BiotechLipids in Health and Disease 2008, 7:48 http://www.lipidworld.com/content/7/1/48
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Inc. (Akita, Japan) [22], and plasma glucose levels were
measured by the Glucose CII Test Wako (Wako Pure
Chemical Industries, Ltd, Tokyo, Japan).
C26:0 Quantification and Fatty Acid Composition 
Analyses
MPMs (1.5 × 107 cells) were rinsed with PBS(-) and total
lipid was extracted by the Folch method [23]. The extract
was then transmethylated with 14% boron trifluoride
methanol solution at 90°C for 90 min. Quantification of
C22:0 and C26:0 was performed with a gas chromatogra-
phy-mass spectrometry (GS-MS) system (QP2010, Shi-
madzu Corporation, Kyoto, Japan) equipped with a fused
silica capillary column (Rtx-5 MS, 30 m × 0.25 mm i.d.;
0.25 μm film thickness, Restek, USA) using nonacosanoic
acid (C29:0) methyl ester as an internal standard. The
mass spectrum acquisitions of C22:0, C26:0, and C29:0
methyl esters were performed in selected-ion monitoring
(SIM) mode and the target ions of these fatty acid methyl
esters were 354.50, 410.40, and 452.40 m/z, respectively.
For fatty acid composition analysis, total lipid extract
from MPMs was transmethylated as described above and
incubated at 90°C for 60 min. The measurement of fatty
acids was performed with a GC-FID system (6890N, Agi-
lent technologies, Tokyo, Japan) equipped with a fused
silica capillary column (Omegamax 250, 30 m × 0.25 mm
i.d.; 0.25 μm film thickness, Supelco, USA) using tricose-
noic acid (C23:0) methyl ester as an internal standard.
Nitrite Assay
The production of NO was determined by Griess reagent
solution [24]. MPMs (1.0 × 105 cells/well) were seeded in
a 96-well flat-bottom plates and stimulated with various
concentrations (1, 10, 100 ng/ml) of LPS plus 2 ng/ml
IFN-γ for 24 h for dose-dependent analysis. Control
media contained neither LPS nor IFN-γ. For time-depend-
ent analysis, MPMs were stimulated with 10 ng/ml of LPS
plus 2 ng/ml IFN-γ and incubated for various times (0, 12,
18, 24 h). After incubation, 50 μl of cell culture superna-
tant was mixed with 100 μl of Greiss reagent solution (1%
sulfanilamide and 0.1% naphthylethylenediamine dihy-
drochloride in 2.5% H3PO4, respectively) and incubated
for 10 min at room temperature. Absorbance of the mix-
ture was measured at 550 nm in a microplate reader
(Corona, Ibaraki, Japan) and NO concentration was
determined using a serial dilution (1 to 125 μM final con-
centrations) of NaNO2 in culture medium as a standard.
The levels of NO production were normalized to cell viab-
litiy using CellTiter-Glo Luminescent Cell Viability Assay
(Promega, WI, USA).
Real-time Quantitative Reverse Transcription-PCR for 
iNOS
MPMs (1.0 × 106 cells/well) were seeded in 6-well flat-bot-
tom plates and stimulated with 10 ng/ml LPS plus 2 ng/
ml IFN-γ for 18 hours. Then, total RNA was extracted
using Trizol (Invitrogen, CA, USA) following the manu-
facturer's protocol. Total RNA (40 ng/each reaction) was
reverse transcribed into cDNA using random primers
(High Capacity cDNA Reverse Transcription kit; Applied
Biosystems, CA, USA) at 25°C for 10 min, 37°C for 120
min, and 85°C for 5 s. For PCR amplification, 4 μl of
reverse transcription reaction was added to a 16 μl reac-
tion mixture containing TaqMan Fast Universal PCR Mas-
ter Mix (Applied Biosystems, CA, USA) and TaqMan Gene
Expression Assays reagents (Applied Biosystems, CA,
USA) for iNOS (Mm00440485_m1). The β-actin gene
(Mm00607939_s1) was amplified in the same experi-
ment to serve as the reference gene. The reaction was car-
ried out in an Applied Biosystems 7500 Fast Real-Time
PCR System at 95°C for 20 s, cycled at 95°C for 3 s and
60°C for 30 s for 40 cycles. The mRNA expression levels
were normalized to those of β-actin.
Intracellular Reactive Oxygen Species (ROS) Assay
To measure ROS levels in MPMs, flow cytometric analysis
was conducted with DCFH-DA [25]. MPMs (1.0 × 106
cells/well) were seeded in 6-well flat-bottom plates then
incubated with 10 μM of DCFH-DA in PBS(-) for 15 min
at 37°C. After incubation, MPMs were rinsed with PBS(-)
to remove unincorporated DCFH-DA and then stimulated
with 0.5 μg/ml of PMA for 20 min at 37°C. To stop reac-
tion, MPMs were rinsed with PBS(-) and gently scraped
with a cell scraper. Cell suspensions were transferred to a
tube and washed twice with cold PBS(-). Cellular fluores-
cence was determined using a FACSCanto flow cytometer
(BD Biosciences, USA). Intracellular fluorescence was
measured at 530/30 nm after excitation of cells at 488 nm
with an argon ion laser. MPMs were discerned by the com-
bination of forward-scattered and side-scattered laser light
and aggregated and/or fragmented cells were excluded.
10,000 events were recorded for analyses.
Quantification of Pro-inflammatory Cytokine Production
MPMs (1.0 × 105 cells/well) were seeded in 96-well flat-
bottom plates and stimulated with 10 ng/ml LPS plus 2
ng/ml of IFN-γ for 24 h. Culture supernatants were col-
lected and cytokines (IL-6, TNF-α and IL-12p70) in media
were measured by flow cytometer using the cytometric
bead array (CBA) method (Mouse inflammation kit; BD
Biosciences, USA) according to the manufacturer's
instructions. Data were acquired using a FACS Canto flow
cytometer (BD Biosciences, USA) and analyzed using BD
cytometric bead array software (BD Biosciences, USA).
The levels of pro-inflammatory cytokines production were
normalized to cell viability using the CellTiter-Glo Lumi-
nescent Cell Viability Assay (Promega, WI, USA).
Statistical Analysis
All values are expressed as mean ± SD. Statistical analysis
was performed with a two-sided Student's t-test using SASLipids in Health and Disease 2008, 7:48 http://www.lipidworld.com/content/7/1/48
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software (version 9.1.3; SAS Institute, Cary, NC). Differ-
ences were considered significant at P < 0.05.
Results
Body Weight, Plasma Lipid, and Glucose Levels in Mice
Table 1 shows levels of body weight, plasma lipids, and
glucose in each group. Average body weight for ALDP-
deficient mice was significantly higher than that for wild-
type mice (P < 0.05). The levels of plasma TG, TC, VLDL-
C, LDL-C, HDL-C, or glucose were not significantly differ-
ent between the two groups.
Quantification of C26:0
The concentration of C26:0 and the ratio of C26:0/C22:0
in MPMs are shown in Fig. 1A and 1B, respectively. Both
C26:0 concentrations and C26:0/C22:0 in MPMs from
ALDP-deficient mice were significantly higher compared
with those of wild-type mice (P  < 0.05 and P < 0.01,
respectively).
Fatty Acid Composition of MPMs
Fatty acid composition in MPMs is shown in Table 2.
There was no significant difference in relative percentage
of total saturated fatty acids (SFA) between the two
groups. However, MPMs from ALDP-deficient mice had a
significantly lower relative percentage of behenic acid
(C22:0) (P < 0.01) and a significantly higher relative per-
centage of lignoceric acid (C24:0) (P < 0.01) than those
from wild-type mice. The relative percentage of total n-6
polyunsaturated fatty acid (n-6 PUFA) was similar
between the two groups. However, the relative percentage
of linoleic acid (LA: C18:2n-6) was significantly higher
than that of wild-type mice. Although, there were no sig-
nificant differences in n-3 PUFA or n-6 PUFA between the
two groups, the ratio of n-3/n-6 was significantly lower in
ALDP-deficient mice than in wild-type mice (P < 0.05).
Dose- and Time-Dependent NO Production and iNOS 
Gene Expression
As shown in Fig. 2A, increased NO production of MPMs
from ALDP-deficient mice was observed at medium (P <
0.05) and high (P < 0.05) doses compared with that of
wild-type mice. As shown in Fig. 2B, NO production in
MPMs from ALDP-deficient mice was significantly higher
compared with those from wild-type mice at 18 h and 24
h (both P < 0.01). Fig. 2C shows iNOS gene expression.
iNOS gene expression was significantly higher in MPMs
from ALDP-deficient mice than in those from wild-type
mice (P < 0.05).
Intracellular ROS Production
Fig. 3 shows that intracellular ROS production levels were
significantly higher in MPMs from ALDP-deficient mice
than in those of wild-type mice (P < 0.05).
Pro-Inflammatory Cytokine Production
As shown in Fig. 4, the production of TNF-α, IL-6, and IL-
12p70 in MPMs from ALDP-deficient mice was signifi-
cantly higher than in those from wild-type mice after treat-
ment with LPS and IFN-γ for 24 h (all, P < 0.05).
Discussion
The present study firstly demonstrated that 1) macro-
phages from ALDP-deficient mice had significantly higher
levels of VLCSFA, such as C24:0 and C26:0, compared
with those from wild-type mice, 2) VLCSFA-accumulated
macrophages had significantly higher production of
inducible NO and pro-inflammatory cytokines, 3)
Table 2: Fatty acid composition in macrophages
Fatty acids Wild-type
(% of total lipid)
ALDP-deficient
(% of total lipid)
C14:0 1.08 ± 0.21 1.18 ± 0.26
C16:0 21.27 ± 0.96 20.77 ± 0.62
C16:1n-7 2.66 ± 0.24 2.82 ± 0.56
C18:0 14.37 ± 0.47 14.65 ± 1.19
C18:1n-9 9.45 ± 0.80 9.74 ± 0.61
C18:2n-6 11.65 ± 0.27 12.52 ± 0.60**
C18:3n-3 0.27 ± 0.09 0.26 ± 0.06
C20:0 0.27 ± 0.13 0.32 ± 0.11
C20:3n-6 1.37 ± 0.16 1.40 ± 0.14
C20:4n-6 9.82 ± 0.35 9.31 ± 0.52
C20:5n-3 0.34 ± 0.05 0.34 ± 0.06
C22:0 0.40 ± 0.04 0.34 ± 0.04**
C22:4n-6 2.68 ± 0.13 2.54 ± 0.18
C22:5n-3 2.67 ± 0.30 2.45 ± 0.18
C24:0 0.59 ± 0.05 0.69 ± 0.06**
C22:6n-3 4.44 ± 0.40 4.16 ± 0.27
SFA 37.98 ± 1.18 37.94 ± 0.91
n-6 PUFA 25.52 ± 0.69 25.77 ± 0.74
n-3 PUFA 7.73 ± 0.51 7.21 ± 0.38
n-3/n-6 0.30 ± 0.02 0.28 ± 0.01*
n-3/AA 0.79 ± 0.04 0.78 ± 0.06
Data represents mean ± SD, n = 8. ALDP, adrenoleukodystrophy 
protein; SFA, saturated fatty acid; PUFA, polyunsaturated fatty acid; 
AA, arachidonic acid. *P < 0.05, **P < 0.01 for comparison with wild-
type.
Table 1: Body weight, plasma lipid, and glucose levels in mice
Wild-type ALDP-deficient
Body weight (g) 25.8 ± 1.8 28.2 ± 2.4*
TG (mg/dL) 49.9 ± 13.6 57.9 ± 10.1
TC (mg/dL) 93.3 ± 5.8 95.7 ± 6.8
VLDL-C (mg/dL) 4.53 ± 1.0 4.80 ± 1.1
LDL-C (mg/dL) 10.7 ± 1.1 10.3 ± 1.3
HDL-C (mg/dL) 77.9 ± 5.0 80.5 ± 7.7
Glucose (mg/dL) 214 ± 77 213 ± 57
Data represents mean ± SD, n = 10. ALDP, adrenoleukodystrophy 
protein; TG, triglyceride; TC, total cholesterol; VLDL-C, very low-
density lipoprotein cholesterol, LDL-C, low-density lipoprotein 
cholesterol, HDL-C, high-density lipoprotein cholesterol. *P < 0.05 
for comparison with wild-type.Lipids in Health and Disease 2008, 7:48 http://www.lipidworld.com/content/7/1/48
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Levels of C26:0 in macrophages Figure 1
Levels of C26:0 in macrophages. Total lipid was extracted from macrophages using the Folch method, and C26:0 and 
C22:0 were measured with the GC-MS system, adding C29:0 as an internal standard. (A) Concentrations of C26:0 in macro-
phages. (B) C26:0/C22:0 ratio in macrophages. Results are expressed as mean ± SD, n = 8. * P < 0.05 for comparison with wild-
type.
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NO production and iNOS gene expression in macrophages Figure 2
NO production and iNOS gene expression in macrophages. (A) Cells were incubated with LPS (1, 10, 100 ng/ml) plus 
IFN-γ (2 ng/ml) for 24 h at 37°C. Control contained neither LPS nor IFN-γ. After incubation, culture supernatants were col-
lected and NO was measured with Griess reagent. (B) Cells were incubated with LPS (10 ng/ml) plus IFN-γ (2 ng/ml) for indi-
cated period at 37°C. After incubation, culture supernatants were collected and NO was measured with Griess reagent. 
Results are expressed as mean ± SD, n = 6. (C) Cells were incubated with LPS (10 ng/ml) plus IFN-γ (2 ng/ml) for 18 h at 37°C. 
After incubation, total RNA was extracted and iNOS gene expression was analyzed by real-time RT-PCR. Results are mean-
fold increase in iNOS mRNA levels of MPMs from ALDP-deficient mice compared with those of wild-type mice and expressed 
as mean ± SD, n = 6. * P < 0.05 for comparison with wild-type.
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VLCSFA-accumulated macrophages also exhibited signifi-
cantly higher levels of intracellular ROS production com-
pared with those of wild-type mice. These results
suggested that VLCSFA accumulation in macrophages
might contribute to pathogenesis of inflammatory dis-
eases through the enhancement of inflammatory and oxi-
dative responses.
The present study showed that VLCSFA-accumulated mac-
rophages from ALDP-deficient mice had significantly
increased NO and intracellular ROS production com-
pared with macrophages from wild-type mice. These
results were concordant with a previous study in which
C26:0-enriched C6 glial cells had increased production of
NO and O2
- after treatment with LPS or oxLDL [13].
Another study reported that C24:0 as well as C26:0 acti-
vated NADPH oxidase in human dermal fibroblasts [26].
Our study also confirmed high levels of iNOS mRNA
expressions in macrophages from ALDP-deficient mice.
Treatment with LPS and pro-inflammatory cytokines,
such as TNF-α and IFN-γ, stimulates iNOS expression by
activating nuclear factor-kappa B (NF-κB) in macrophages
[27,28]. Although the precise mechanism of the intracel-
lular pathway is still unknown, our results suggest that
VLCSFA accumulation in macrophages may induce NF-κB
activity after LPS and IFN-γ treatment. It has been reported
that excess production of NO followed by activated iNOS
influence the pathogenesis of inflammatory diseases, such
as atherosclerosis. High levels of NO induce apoptosis of
vascular smooth muscle cell through enhancing Fas/Fas-L
interactions, which promote plaque instabilities [29,30].
In addition, interaction of NO and O2
- rapidly generates
peroxynitrite (ONOO-), which has injurious effects on
vascular cells through modification of lipid, protein, and
DNA [31-33]. As we recently reported high levels of C26:0
and C24:0 in red blood cells of patients with coronary
artery disease and metabolic syndrome, VLCSFA-accumu-
lated macrophages might contribute to the initiation and
Intracellular ROS productions in macrophages Figure 3
Intracellular ROS productions in macrophages. Cells were incubated with 10 μM of DCFH-DA for 15 min, and then 
stimulated with 0.5 μg/ml of PMA for 20 min at 37°C. Fluorescence of DCF was measured by a flow cytometer as described in 
Methods. Values are mean-fold increase of relative DCF fluorescence intensity compared with non-stimulated control and 
expressed as mean ± SD, n = 6. * P < 0.05 for comparison with wild-type.
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Pro-inflammatory cytokine production in macrophages Figure 4
Pro-inflammatory cytokine production in macrophages. Cells were incubated with LPS (10 ng/ml) plus IFN-γ (2 ng/ml) 
for 24 h at 37°C. After incubation, culture supernatants were collected and TNF-α (A), IL-6 (B), and IL-12p70 (C) were meas-
ured by cytometric bead assay method as described in Methods. Results are expressed as mean ± SD, n = 6. * P < 0.05 for 
comparison with wild-type.
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progression of atherosclerosis through the enhanced pro-
duction of NO and ROS.
The production of pro-inflammatory cytokines was
increased in macrophages from ALDP-deficient mice.
These findings were consistent with previous studies using
C26:0-enriched C6 glial cells [13] and PBMC from X-ALD
patients [11,12]. In the present study, we firstly demon-
strated not only enhanced production of a variety of pro-
inflammatory cytokines, but also the accumulation of
VLCSFA in detail, utilizing macrophages from ALDP-defi-
cient mice. The increased levels of VLCSFA, such as C24:0
and C26:0, were clearly observed in macrophages from
the ALDP-deficient mice. Although the relative percent-
ages of total n-6 PUFA or n-3 PUFA, including eicosapen-
taenoic acid (EPA: C20:5n-3) and docosahexaenoic acid
(DHA: C22:6n-3), were not significantly different
between the two groups, the ratio of n-3/n-6 was signifi-
cantly deceased in macrophages from the ALDP-deficient
mice compared with those from wild-type mice. The fea-
ture of susceptibility to inflammatory and oxidative
responses in macrophages from the ALDP-deficient mice
could derive from the low ratio of n-3/n-6; however, the
ratio of n-3/arachidonic acid (AA: C20:4n-6) was similar
between the two groups. Therefore, we believe that the
findings of the present study were caused mainly by
VLCSFA accumulation in macrophages.
Although we have not confirmed that ALDP-deficient
mice have the features of metabolic syndrome and/or cor-
onary artery disease compared to wild-type mice, body
weight was higher in ALDP-deficient mice than wild-type
mice. A previous study reported that plasma TC levels
were elevated in the ALDP-deficient mice [34]; however,
the levels of TC, TG, LDL-C or HDL-C, were not signifi-
cantly different between the ALDP-deficient mice and the
wild-type mice in the present study. Further analysis is
needed to clarify the mechanism behind differences of
body weight between the two groups.
Conclusion
VLCSFA-accumulated macrophages show enhanced pro-
duction of NO, ROS, and pro-inflammatory cytokines,
suggesting that VLCSFA accumulation in macrophages
may contribute to the pathogenesis of inflammatory dis-
eases through the enhancement of inflammatory and oxi-
dative responses. Further studies are needed to investigate
the direct evidence for VLCSFA accumulation inducing
inflammatory disease such as coronary artery disease.
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